Ulusan Bağcı Özlem, Caner Ayşe
Ege University Faculty of Medicine, Department of Parasitology, Izmir, Turkey.
Ege University, Institute of Health Sciences, Department of Bioinformatics, Izmir, Turkey.
Mikrobiyol Bul. 2021 Jan;55(1):67-80. doi: 10.5578/mb.20092.
Leishmaniasis is a disease caused by the genus Leishmania spp., which are intracellular parasites. Depending on parasite species and host immune response, there are three basic clinical forms of the disease: cutaneous, mucocutaneous, and visceral leishmaniasis. Cutaneous leishmaniasis is a chronic disease and characterized by the presence of ulcerated skin lesions. The type of skin pathology seen during disease is determined in part by the infecting Leishmania spp., but also by a combination of inflammatory and antiinflammatory host immune response factors resulting in diverse clinical outcomes. In this study, it was aimed to determine the genes, molecular signaling mechanisms and biological functions of the molecules that play a role in the pathogenesis of the disease and immune response and determine host-parasite interactions in mice that are naturally resistant and susceptible to Leishmania major and Leishmania braziliensis. For this, transcriptomic series GSE56029 was downloaded from "Gene Expression Omnibus"(GEO) data base, including expression profiling of twenty-four tissue samples that were recovered from both naive mice and mice (BALB/c, C57BL/6) infected with L.major and L.braziliensis. Then, "Differentially Expressed Genes" (DEGs) were identified by limma package in R script. FDR q<0.05 and absolute log2FC> 2 as threshold values were accepted in the analysis. Subsequently, functional and pathway enrichment analyses were performed for the DEGs by "Ingenuity Pathway Analysis" (IPA). For each of DEGs, p<0.01, FDR q<0.01, and absolute log2FC> 1 were used and analyzed with the software program IPA 8.0. Ingenuity Pathway Analysis revealed the most enrichment pathways to be the inflammation, dendritic cell maturation and "Triggering Receptor Expressed on Myeloid Cells 1" (TREM-1) signal mechanisms and that the DEGs related to the regulation of immune system process were closely associated with the progress of cutaneous leishmaniasis. The upstream regulator analysis predicted that TNF-α, IFNy, IL-1 β, IL-10RA and "Signal Transducer and Activator of Transcription-1" (STAT-1) are the regulators that explained gene expression changes causing biological activities in the tissues. Chemical compounds that may have anti-leishmanial effects were also identified in the study. In this study, the mechanisms belonging to the parasite species and host that determine the resistance/susceptibility phenotype were attempted to elucidate. Assessment of gene expression patterns, cytokine/chemokines, and signaling pathways in BALB/c and C57BL/6 mice infected with L.major and L.braziliensis will provide a better understanding of the potential mechanisms underlying infection from a genetic perspective. These results may guide for the future studies in terms of developing potential biomarkers for the diagnosis and prognosis prediction of cutaneous leishmaniasis and providing information about new treatment targets.
利什曼病是由利什曼原虫属物种引起的疾病,这些原虫是细胞内寄生虫。根据寄生虫种类和宿主免疫反应,该疾病有三种基本临床形式:皮肤利什曼病、黏膜皮肤利什曼病和内脏利什曼病。皮肤利什曼病是一种慢性病,其特征是存在溃疡性皮炎损。疾病期间所见的皮肤病理类型部分由感染的利什曼原虫属物种决定,但也由炎症和抗炎宿主免疫反应因子的组合导致不同的临床结果。在本研究中,旨在确定在该疾病发病机制和免疫反应中起作用的分子的基因、分子信号传导机制和生物学功能,并确定对硕大利什曼原虫和巴西利什曼原虫天然抗性和易感性小鼠中的宿主 - 寄生虫相互作用。为此,从“基因表达综合数据库”(GEO)下载了转录组系列GSE56029,包括从未感染小鼠以及感染硕大利什曼原虫和巴西利什曼原虫的小鼠(BALB/c、C57BL/6)中回收的24个组织样本的表达谱。然后,在R脚本中使用limma软件包鉴定“差异表达基因”(DEG)。分析中接受FDR q<0.05和绝对log2FC>2作为阈值。随后,通过“ Ingenuity通路分析”(IPA)对DEG进行功能和通路富集分析。对于每个DEG,使用p<0.01、FDR q<0.01和绝对log2FC>1,并使用软件程序IPA 8.0进行分析。 Ingenuity通路分析显示最富集的通路是炎症、树突状细胞成熟和“髓系细胞上表达的触发受体1”(TREM-1)信号机制,并且与免疫系统过程调节相关的DEG与皮肤利什曼病的进展密切相关。上游调节因子分析预测TNF-α、IFNy、IL-1β、IL-10RA和“信号转导和转录激活因子-1”(STAT-1)是解释导致组织中生物学活性的基因表达变化的调节因子。该研究中还鉴定了可能具有抗利什曼原虫作用的化合物。在本研究中,试图阐明决定抗性/易感性表型的寄生虫物种和宿主的机制。评估感染硕大利什曼原虫和巴西利什曼原虫的BALB/c和C57BL/6小鼠中的基因表达模式、细胞因子/趋化因子和信号通路将从基因角度更好地理解感染的潜在机制。这些结果可能为未来研究提供指导,以开发皮肤利什曼病诊断和预后预测的潜在生物标志物,并提供有关新治疗靶点的信息。
ACS Infect Dis. 2019-8-9
PLoS Pathog. 2013-7-18
PLoS Negl Trop Dis. 2016-9-15